RNS Number : 9745W
Convatec Group PLC
17 March 2026
17 March 2026
Convatec Group Plc
("Convatec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").
Vesting of Awards under the Company's Long Term Incentive Plan ("LTIP") and Deferred Bonus Plan ("DBP")
On 15 March 2026, conditional share awards granted to each of Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer in 2023 under the LTIP in the form of Performance Share Awards ("PSA") vested and were released to them on 16 March 2026.
Additionally, on 15 March 2026, awards granted to each of Jonny Mason in 2023 under the DBP in the form of Restricted Stock Units ("RSU") and awards granted to Fiona Ryder in 2023 under the LTIP in the form of RSUs also vested and were released to them on 16 March 2026.
For all awards released to the PDMRs, on 16 March 2026 sufficient shares were sold to satisfy income tax and National Insurance ("NI") liabilities, with the balance of shares retained by the PDMRs, as summarised in the table below:
PDMR
Share Award
Shares vested
Shares sold to satisfy income tax & NI liabilities
Share price
Total shares acquired
Jonny Mason
PSA
511,469
241,114
£2.344
270,355
Jonny Mason
DBP
106,137
50,035
£2.344
56,102
Fiona Ryder
PSA
27,001
12,729
£2.344
14,272
Fiona Ryder
RSU
31,748
14,967
£2.344
16,781
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Jonny Mason
2
Reason for the notification
a)
Position/status
Chief Executive Officer and PDMR
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Convatec Group Plc
b)
LEI
213800LS272L4FIDOH92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Vesting of PSA under the LTIP. b. Vesting of RSU under the DBP.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£0
511,469
b.
£0
106,137
d)
Aggregated information
- Aggregated volume
617,606
- Price
£0
e)
Date of the transaction
2026-03-15
f)
Place of the transaction
Outside a trading venue
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Immediate sale of shares awarded under the LTIP to cover tax and national insurance liabilities. b. Immediate sale of shares awarded under the DBP to cover tax and national insurance liabilities.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£2.344
241,114
b.
£2.344
50,035
d)
Aggregated information
- Aggregated volume
291,149
- Price
£2.344
e)
Date of the transaction
2026-03-16
f)
Place of the transaction
XLON
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Fiona Ryder
2
Reason for the notification
a)
Position/status
Chief Financial Officer and PDMR
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Convatec Group Plc
b)
LEI
213800LS272L4FIDOH92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Vesting of PSA under the LTIP. b. Vesting of RSU under the LTIP.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£0
27,001
b.
£0
31,748
d)
Aggregated information
- Aggregated volume
58,749
- Price
£0
e)
Date of the transaction
2026-03-15
f)
Place of the transaction
Outside a trading venue
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Immediate sale of shares awarded under the LTIP to cover tax and national insurance liabilities. b. Immediate sale of RSUs awarded under the LTIP to cover tax and national insurance liabilities.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£2.344
12,729
b.
£2.344
14,967
d)
Aggregated information
- Aggregated volume
27,696
- Price
£2.344
e)
Date of the transaction
2026-03-16
f)
Place of the transaction
XLON
Enquiries
James Kerton, Company Secretary
Email: cosec@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFIIVTIDLIR
